Suraksha Diagnostics, a leading diagnostics chain in Eastern India, has launched one of the region’s largest and most advanced Genomics Laboratories. The grand inauguration was graced by Prof. Sukumar Mukherjee, a renowned rheumatologist and mentor at Suraksha Diagnostics.
With the global genetic testing market projected to grow from $38.77 billion in 2024 to $186.64 billion by 2035 (CAGR: 22.5%), Suraksha’s investment marks a major milestone in India’s journey toward precision medicine. The company has invested ₹22 crore in the current facility and plans an additional ₹46 crore over the next two years to establish one of Asia’s most advanced genomics centres.
The state-of-the-art lab features a comprehensive suite of genomic technologies, including Cytogenetics, Microarray, Sanger Sequencing, and multiple Next-Generation Sequencers (NGS). These capabilities enable a wide range of genetic testing to support predictive, preventive, and personalised healthcare.
The lab specializes in prenatal genetic screening for chromosomal abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome, as well as sex chromosome aneuploidies and microdeletions. Expert genetic counseling is provided to support informed decision-making for expecting parents.
In oncology, Suraksha’s Genomics Lab is pioneering onco-genomics through advanced hereditary cancer panels, germline and somatic mutation profiling, and NGS-powered targeted panels. These tools aid in early detection, personalized risk assessment, and precision treatment planning for cancers like breast, ovarian, and colorectal.
This initiative positions Suraksha Diagnostics as a frontrunner in precision diagnostics in Eastern and North-Eastern India.